Allergan has received its first FDA decision since officially becoming a part of AbbVie. And it’s bad news. Regulators have spurned abicipar, the neovascular age-related macular degeneration (wet AMD) drug that Allergan chief Brent Saunders had touted as one of four “expected” approvals just before announcing the $63 billion sale. The company said the complete … Continue reading AbbVie’s first post-merger Allergan drug pitch strikes out with the FDA as regulators turn thumbs down on Lucentis challenger